alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › immunoassay

immunoassay

7 studies tagged immunoassay, dated 2018-12-08 to 2025-01-02. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer's disease biomarkers 2025-01-02
  2. Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment 2024-10-16
  3. Evaluation of core Biomarkers of Alzheimer's disease in saliva and plasma measured by chemiluminescent enzyme immunoassays on a fully automated platform 2024-07-12

Studies

7 studies carry this tag.

Date range

2018 to 2025

Top journals

  • Alzheimer's research & therapy 2
  • Scientific reports 2
  • Alzheimer's & dementia (Amsterdam, Netherlands) 1
  • Journal of neurology, neurosurgery, and psychiatry 1
  • Nature communications 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer's disease biomarkers

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Nature communications 2025-01-02 Biomarkers

    Different forms of phosphorylated tau (p-tau) have shown strong potential as Alzheimer's disease (AD) biomarkers in both cerebrospinal fluid (CSF) and plasma.

  2. Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of neurology, neurosurgery, and psychiatry 2024-10-16 Biomarkers

    Plasma pTau217 and pTau181 both correlate with AD, but the fold change in pTau217 makes it better to diagnose cerebral amyloidosis, and predict cognitive decline and conversion to AD dementia.

  3. Evaluation of core Biomarkers of Alzheimer's disease in saliva and plasma measured by chemiluminescent enzyme immunoassays on a fully automated platform

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Scientific reports 2024-07-12 Biomarkers

    Cerebrospinal fluid (CSF) core biomarkers of Alzheimer's disease (AD), including amyloid peptide beta-42 (Aβ42), Aβ42/40 ratio, and phosphorylated tau (pTau), are precious tools for supporting AD diagnosis.

  4. Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Scientific reports 2024-01-05 Biomarkers

    A growing literature suggests that plasma levels of tau phosphorylated at amino acid 217 (pTau217) performs similarly to cerebrospinal fluid (CSF) biomarkers and PET imaging to detect amyloid pathology and to provide diagnostic and prognostic information in Alzheimer's disease (AD), but a significant limiting factor thus far has been a lack of widely available immunoassays.

  5. Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's research & therapy 2022-06-23 Biomarkers

    The plasma Aβ42/Aβ40 ratio measured using the HISCL series achieved high accuracy in predicting amyloid PET status.

  6. Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2021-02-06 Biomarkers

    The Lumipulse platform provides comparable sensitivity and specificity to established CSF immunoassays in identifying pre-symptomatic AD pathology.

  7. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's research & therapy 2018-12-08 Biomarkers

    The measurement of plasma Aβ peptides with an immunological assay can be improved by preconcentration via immunoprecipitation with an antibody against the Aβ amino-terminus and elution of the captured peptides by heating in a mild detergent-containing buffer.

All topic tags with their study counts